ArticleDiscover oncology2026
A bibliometric and visual analysis of colorectal cancer-diabetes comorbidity.
Article in Discover oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundColorectal cancer (CRC), a leading cause of global cancer-related mortality, exhibits a complex bidirectional relationship with diabetes mellitus (DM). Epidemiological evidence indicates that DM significantly increases the risk of CRC, while CRC progression may exacerbate diabetic complications; however, the underlying mechanisms remain incompletely understood. This study aimed to conduct a bibliometric analysis of the literature on COLORECTAL CANCER-DIABETES comorbidity to identify research trends, collaborative networks, and emerging thematic foci.
methodsWe performed a comprehensive search in the Web of Science Core Collection (WoSCC) database to retrieve relevant literature. Using analytical and visualization tools, including CiteSpace and VOSviewer, we examined publication trends, major contributing countries and institutions, collaboration networks, and keyword evolution to map the current research landscape in this field.
resultAnnual publication output on COLORECTAL CANCER-DIABETES comorbidity increased markedly after 2005, reflecting growing recognition of the metabolic-cancer interplay and expanded research funding. The United States and China were the dominant contributors, with Harvard University and Birmingham Women's Hospital among the most productive institutions. Keyword analysis revealed emerging research clusters such as "diabetes-associated centrosome amplification," "metformin's therapeutic potential," and "anastomotic leakage."
conclusionResearch on the interplay between colorectal cancer and diabetes is gaining increasing priority. Future efforts should focus on elucidating molecular mechanisms-such as oxidative stress and angiogenesis dysregulation-refining epidemiological models, and translating findings into clinical practice. Developing precision medicine strategies for CRC screening and treatment in diabetic populations, alongside the exploration of novel biomarkers and therapeutic targets, will be essential to improve patient prognosis.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.